NPS PHARMACEUTICALS INC 4
4 · NPS PHARMACEUTICALS INC · Filed Dec 10, 2014
Insider Transaction Report
Form 4
Selisker Rachel R
Director
Transactions
- Exercise/Conversion
Stock Options (right to buy)
2014-12-08−23,157→ 1,208 totalExercise: $4.24Exp: 2019-09-23→ Common Stock (23,157 underlying) - Exercise/Conversion
Common Stock
2014-12-08$4.24/sh+23,157$98,186→ 33,057 total - Sale
Common Stock
2014-12-08$34.50/sh−23,157$798,981→ 9,900 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.50 to $34.53, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- [F3]On September 23, 2009, the reporting person received a grant of 36,000 stock options under the Issuer's 2005 Omnibus Incentive Plan. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first anniversary of the date of grant and 6.25% every three months thereafter. As of the date of this filing, all 36,000 stock options have vested.